ClinicalTrials.Veeva

Menu
S

Sheffield Children's NHS Foundation Trust | Sheffield Children's Hospital - Clinical Research Facility

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMN 111
Posoleucel
Gemtuzumab
Glucose
Fesoterodine
UX007
IV tetracosactide
daunorubicin
Cyclophosphamide
PF-04965842

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 47 total trials

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a hei...

Active, not recruiting
Achondroplasia
Biological: vosoritide

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Enrolling
Respiratory Syncytial Virus (RSV)
Drug: EDP-938
Drug: Placebo

The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1...

Enrolling
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Drug: Cannabidiol Oral Solution [Epidiolex]

This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 i...

Active, not recruiting
Achondroplasia
Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia

Active, not recruiting
Achondroplasia
Drug: BMN 111

The main purpose of this study is :1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can b...

Enrolling
Acute Myeloid Leukaemia
Drug: Cyclophosphamide
Drug: Mitoxantrone

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs...

Active, not recruiting
Osteogenesis Imperfecta
Other: Placebo
Biological: Setrusumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

NHS Foundation Trust logo
BioMarin Pharmaceutical logo
Pfizer logo
University College London (UCL) logo
Ultragenyx logo
C
Allergan logo
A
Enanta Pharmaceuticals logo
Jazz Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems